Activity Downloads

To Participate

To participate in this continuing education activity:

1. Review the activity description and objectives.
2. View the activity.
3. Complete the online post-test and activity evaluation.

Note: If you attended the live CE activity AND received CE credit (i.e. a pharmacist CE statement of credit with ACPE UAN 0221-9999-20-019-L01-P), you are NOT allowed to also receive credit for this home-study on-demand web activity.

 

Co-produced by ProCE, the National Association of Specialty Pharmacy (NASP), and AllianceRx Walgreens Prime.

Activity Description

Pharmacists in a variety of practice settings play vital roles in the multidisciplinary care team for the lung cancer patient. Throughout the lifecycle of disease management, lung cancer patients will likely be treated in both in-patient and outpatient environments and require deliberate care coordination. Clinical pharmacists, who may specialize broadly in oncology or practice in lung cancer specifically, must have an in-depth understanding of the unique multiple factors that lead to treatment decisions. Other pharmacist practice areas, such as specialty community pharmacy, are exponentially evolving as oral oncology agents increase. Advances in the utilization of biomarkers and subsequent targeted therapies have exploded, and thorough evaluation of patients is critical to correctly diagnose and treat lung cancer. As integral members of the healthcare team, pharmacists involved in oncology require a working knowledge or mastery of treatment options, including appropriateness of therapy, staging consideration, treatment failure, and associated adverse effects.

Learning Objectives

The target audience for this activity includes pharmacists. At the completion of this activity, the participant will be better able to:

• Describe the etiology and pathophysiology of NSCLC and SCLC lung cancer.
• Outline treatment options for NSCLC and SCLC including the mechanisms of action, efficacy, and monitoring of the agents.
• Examine the screening, staging and use of next generation sequencing to identify targetable mutations for the treatment of advanced disease.
• Identify toxicity management strategies for immunotherapy and targeted therapies in the treatment of NSCLC and SCLC.
• Discuss methods to optimize and individualize patient care, including approaches to overcoming therapeutic access barriers.

Faculty

Angie Wood, PharmD, BCPS, BCOP
Clinical Pharmacy Specialist
Trellis Rx

CE Accreditation

Release Date: February 25, 2020
Expiration Date: March 10, 2022

Pharmacists

This activity is jointly provided by ProCE, LLC, the National Association of Specialty Pharmacy (NASP) and AllianceRx Walgreens Prime. ProCE is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-20-019-H01-P has been assigned to this home study knowledge-based activity. This activity is approved for 1.5 contact hours (0.15 CEUs) in states that recognize ACPE providers. The activity is provided at no cost to participants. Participants must complete the online post-test and activity evaluation to receive pharmacy CE credit. Statements of completion will be issued online at www.ProCE.com and proof of completion will be posted in NABP CPE Monitor profiles. No partial credit will be given.

Disclosure

It is the policy of ProCE, LLC to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed during their presentation. Dr. Wood has no relevant commercial or financial relationships to disclose.

Please note: The opinions expressed in this activity should not be construed as those of the CE providers, NASP, AllianceRx Walgreens Prime or Celgene. The information and views are those of the faculty through clinical practice and knowledge of the professional literature. Portions of this activity may include the discussion of drugs for unlabeled indications. Use of drugs outside of labeling should be considered experimental, and participants are advised to consult prescribing information and professional literature.

Funding

This activity is supported by an educational grant from Celgene.

    

The material presented in this CE activity does not reflect the views of ProCE, LLC or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.